Skip to main content
Dermapharm Holding SE logo

Dermapharm Holding SE — Investor Relations & Filings

Ticker · DMP ISIN · DE000A2GS5D8 LEI · 5299009F0KNZINQQQK37 F Manufacturing
Open in API
Filings indexed 245 across all filing types
Latest filing 2026-05-15 Proxy Solicitation & In…
Country DE Germany
Listing F DMP

About Dermapharm Holding SE

https://ir.dermapharm.de/index-EN.php

Dermapharm Holding SE is a manufacturer of branded pharmaceuticals and healthcare products, with a focus on the patent-free segment. The company operates an integrated business model that encompasses the entire value chain, including in-house research and development, production, and distribution. A dedicated pharmaceutical sales force manages the marketing and sales of its brand products. Dermapharm maintains a diversified portfolio concentrated on selected therapeutic areas, allowing it to establish strong market positions. The company operates several production, development, and distribution sites to support its operations and international expansion.

Recent filings

Filing Released Lang Actions
Dermapharm Holding SE: Bekanntmachung der Einberufung zur Hauptversammlung am 26.06.2026 in Munchen mit dem Ziel der europaweiten Verbreitung gema 121 AktG
Proxy Solicitation & Information Statement Classification · 95% confidence The document is the formal notice of convocation (“Einberufung”) of the Annual General Meeting (Hauptversammlung) with detailed agenda items and proposals for shareholder votes. This is not the AGM slide deck but rather the proxy solicitation/information statement inviting votes, consistent with materials sent to shareholders to request voting instructions. Therefore, it should be classified as a Proxy Solicitation & Information Statement (PSI).
2026-05-15 German
Dermapharm Holding SE: Themis Beteiligungs-Aktiengesellschaft, buy
Director's Dealing Classification · 95% confidence The document is a public disclosure of transactions by a person discharging managerial responsibilities (a supervisory board member) acquiring company shares. It follows the standard format for insider dealings notifications (with details of the instrument, date, volume, price, and person). This matches the definition of Director’s Dealing, code DIRS.
2026-05-15 English
Dermapharm Holding SE performs in line with projections in Q1 2026 and confirms guidance
Earnings Release Classification · 78% confidence The document is a corporate press release announcing Dermapharm’s Q1 2026 results, including consolidated revenue, EBITDA, segment performance, and outlook confirmation. It provides key highlights and selected IFRS figures, but it is not the full interim report itself (it refers readers to the full interim statement available online). This aligns with an Earnings Release (ER) rather than a full Interim Report (IR) or Annual Report. Q1 2026
2026-05-13 English
Q1 statement / Q1 financial report 2026
Interim / Quarterly Report Classification · 93% confidence The document is titled “INTERIM STATEMENT Q1 2026” and contains detailed quarterly results for Q1 2026 (revenue, EBITDA, earnings per share, consolidated statement of financial position, income statement, cash flow statement, segment analysis, outlook). It is not merely an announcement but the full interim financial report for the first quarter. This matches the definition of an Interim/Quarterly Report (IR). Q1 2026
2026-05-13 English
Report Publication Announcement 2026
Report Publication Announcement Classification · 95% confidence The document is a preliminary announcement about the upcoming publication of quarterly financial reports and interim statements for Dermapharm Holding SE. It specifies the report type as a quarterly financial report within the first half-year (Q1) and provides disclosure dates and URLs where the full reports will be available. The document itself does not contain the actual financial data or substantive analysis but merely announces the forthcoming release of these reports. The document length is short (2024 characters), and it fits the pattern of a report publication announcement rather than the report itself.
2026-05-04 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 87% confidence The document is a German WpHG Section 41 ‘Total Voting Rights Announcement’ by Dermapharm Holding SE. It provides the new total number of voting rights as of a given date, matching the description of a Voting Rights Announcement. This falls under Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2026-04-20 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.